Skip to main content

Table 2 Treatments and clinical outcomes of patients with COVID-19

From: Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study

  All patients (n = 1190) Survivor (n = 1033) Non-survivor (n = 157) p value
Treatments, n (%)
 Antibiotic 977 (87.7) 859 (87.0) 118 (92.9) 0.0575
 Antifungal 50 (4.5) 35 (3.6) 15 (11.8) < 0.0001
 Antiviral 681 (61.1) 626 (63.4) 55 (43.3) < 0.0001
 Glucocorticoids 289(25.9) 213 (21.6) 76 (59.8) < 0.0001
 Oxygen therapy, n (%)     < 0.0001
  None 203 (17.1) 203 (19.7) 0 (0.0)  
  Nasal cannula 792(66.6) 776 (75.1) 16(10.2)  
  Mask oxygen 27 (2.3) 19 (1.9) 7 (4.5)  
  High-flow nasal cannula 60 (5.0) 24 (2.3) 36 (22.9)  
  Non-invasive mechanical ventilation 62 (5.2) 4 (0.4) 58 (36.9)  
  Invasive mechanical ventilation 42 (3.5) 6 (0.6) 36 (22.9)  
  ECMO 4(0.3) 0 4 (2.6)  
Outcomes
 Duration of MV (IQR), days 5 (2.0, 8.0) 6 (5.0, 9.0) 4 (2.0,8.0) 0.1563
 Duration of ICU stay (IQR), days 6 (3.0, 10.5) 7 (4.0, 11.0) 5 (2.0, 9.0) 0.0522
 Duration of in-hospital stay (IQR), days 11 (7.0, 14.5) 11 (8.0, 15.0) 8 (4.0, 12.0) < 0.0001
 In-hospital mortality, n (%) 157 (13.2) 0 (0.0) 157 (100.0) < 0.0001
  1. ECMO extracorporeal membrane oxygenation, ICU intensive care unit, MV mechanical ventilation